Pharmascience in Brief

About Us

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with over 1 500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 57th among Canada’s top 100 research & development (R&D) investors with over $44 million invested in 2015, Pharmascience Inc. is the 10th largest pharmaceutical company in Canada. Pharmascience Inc. has strong values which are based on the importance of investing in the personal development and life of employees and young people. At the beginning of 2017, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People and named as one of Montreal’s best employers, as part of the Canada’s Top 100 Employers project. Pharmascience Inc. has strong long-standing philanthropic ties with its communities, both locally and internationally. For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as the partner of choice to increase access to medicine. Pharmascience’s total donations of essential medicine, is close to $60 million. Pharmascience Inc. is a leading manufacturer and marketer of prescription; generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. 

 

Pharmascience Quick Facts

  •   1.
    Co-founded by pharmacists Morris Goodman and Ted Wise in 1983;
  •   2.
    Largest pharmaceutical employer in Quebec with 1,500 employees;
  •   3.
    Third largest generic pharmaceutical company in Canada and third largest pharmaceutical company in Canada by number of prescriptions;
  •   4.
    Ranked 57th among Canada's top 100 R&D investors with CAD $44 million invested annually;
  •   5.
    Diversified portfolio of over 400 product families, both prescription and OTC;
  •   6.
    Sales in more than 60 countries;
  •   7.
    One of the largest providers of generic single-source products;
  •   8.
    A leader in customer service & support.

Morris Goodman

Chairman of the Board

As one of Canada's leading entrepreneurs and a pioneer in the generic drug industry, Mr. Goodman has dedicated his career to "Creating the Difference" in healthcare in Canada and worldwide. He graduated from the Faculty of Pharmacy at the University of Montreal in 1953 at the young age of twenty-one.

After graduation, Mr. Goodman focused on the industry side of pharmacy and quickly obtained distribution rights from several international pharmaceutical companies to bring their products to the Canadian marketplace. He marketed and sold these products in Canada under the company name of Winley-Morris Co. Ltd.

In 1971, Mr. Goodman approached a California-based company, International Chemical & Nuclear Corporation (ICN) and became their Canadian distributor of L-Dopa. Impressed with his innovative approach, they purchased Winley-Morris and established Morris Goodman as President of ICN Canada.

In 1983, Mr. Goodman co-founded Pharmascience Inc. with his good friend and colleague, Ted Wise. As Co-Founder & Chairman of the Board of Pharmascience Inc., Morris Goodman has been at the forefront of the company's explosive growth and development, leading it to its current standing as one of the top three generic pharmaceutical companies in Canada.

Notwithstanding his business successes, Mr. Goodman is a leader in philanthropic initiatives. Included among the major charitable donations made by The Morris & Rosalind Goodman Family Foundation are The Stroke Unit at the Jewish General Hospital, the Agora at the Faculty of Pharmacy at the University of Montreal and The Goodman Cancer Research Centre at McGill University.

In May of 2011, McGill University bestowed an honorary degree upon Mr. Goodman.

David Goodman

Chief Executive Officer

Dr. David Goodman is Chief Executive Officer of Pharmascience, which is today the 2nd largest privately-owned pharmaceutical company in Canada.

Dr. Goodman obtained his Bachelor degree in Commerce from McGill University, and his Ph.D. in pharmacology from the University of Virginia. Upon graduation, he began his career at Pharmascience in Business Development and has gained significant experience in progressively senior international and domestic roles.

Under Dr. Goodman's leadership, Pharmascience has gone from being a strictly Canadian company to becoming an important player on the global stage. Pharmascience strives to be the first company to launch its generic pipeline in Canada, Europe and various markets throughout the world.

Dr. Goodman's success is his belief and insistence on major and constant investment in internal and external R&D programs, as well as in employee development.

Jean-Guy Goulet

Chief Operating Officer

Prior to his recent nomination, Mr. Goulet provided market strategy consulting services to healthcare sector organizations operating in Canada and international markets.

Mr. Goulet started his career in 1987 in the Quality Control department at Technilab Pharma, later acquired by Ratiopharm.  He rapidly gained increasing responsibilities in operations, sales, marketing and business development. From 2002 to 2006, he was President of the Commercial division of Ratiopharm Canada, then President of North America from 2006 to 2010.  Mr. Goulet joined Watson Plc in 2011, which was renamed Actavis in 2012. He led Actavis Canada and Latin America until the acquisition by Actavis plc of Allergan in April 2015. He then became President of Actavis Canada, until the sale of this division to a global pharmaceutical company.

Mr. Goulet graduated in Chemistry from University of Montreal. During his career, he invested time and energy in developing and representing the Canadian Generic Pharmaceutical Association as Chairman of the Board from 2002 to 2006, and he was part of the negotiation team during the Federal patent law revisions from 1993 to 2006.  He recently served as a representative of the Generic Pharmaceutical industry on the negotiating committee of the Pan Canadian Pharmaceutical Alliance (pCPA).